Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Declares Pox On Both Houses In Enforcement Letters For Curosurf, Infasurf

This article was originally published in The Pink Sheet Daily

Executive Summary

In separate “notice of violation” letters issued Oct. 31 but posted several days apart, FDA rejected superiority claims on the part of Cornerstone Therapeutics and Ony for their respiratory distress syndrome drugs.

You may also be interested in...

Atralin Acne Gel Awarded “A+” In Valeant Ad, But FDA Sends Promo To Back Of The Class

A clever marketing graphic is dinged because it comes in the context of unjustified superiority claims.

Copaxone Promos Can’t List Risks Product Doesn’t Have, Especially Incorrectly, FDA Warns

The first warning letter of the year from FDA’s Office of Prescription Drug Promotion goes to Teva for web pages and materials displayed at a medical conference that overstated the safety and efficacy of its MS drug Copaxone.

DDMAC To Cornerstone: Zyflo CR Promotions Need Current Safety Labeling

An FDA advertising violation letter for Cornerstone Therapeutics' asthma therapy Zyflo CR should serve to remind industry that providing outdated safety labeling with promotions is a sure way to draw the agency's regulatory scrutiny

Related Content


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts